Tropical Journal of Pharmaceutical Research July 2016; 15 (7): 1515-1524 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 30001 Nigeria. All rights reserved.

> Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v15i7.23

Original Research Article

S-Alkylated/aralkylated 2-(1*H*-indol-3-yl-methyl)-1,3,4oxadiazole-5-thiol derivatives. 1. Synthesis and characterization

Kaniz Rubab¹, Muhammad A Abbasi¹*, Aziz-ur-Rehman¹, Sabahat Z Siddiqui¹ and Muhammad N Akhtar²

¹Department of Chemistry, Government College University, Lahore-54000, Pakistan, ²Faculty of Industrial Sciences & Technology, University Malaysia Pahang, Leburaya TunRazak, Kuantan Pahang, Malaysia

*For correspondence: Email: atrabbasi@yahoo.com, abbasi@gcu.edu.pk; Tel: +92-42-111000010 ext 266

Received:

Revised accepted: 21 April 2016

Abstract

Purpose: To synthesize and characterize S-alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol derivatives.

Methods: 2-(1H-indol-3-yl)acetic acid (1) was reacted with absolute ethanol and catalytic amount of sulfuric acid to form ethyl 2-(1H-indol-3-yl)acetate (2) which was transformed to 2-(1H-indol-3-yl)acetohydrazide (3) by refluxing with hydrazine hydrate in methanol. Ring closure reaction of 3 with carbon disulfide and ethanolic potassium hydroxide yielded 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol (4) which was finally treated with alkyl/aralkyl halides (5a-u) in DMF and NaH to yield S-alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiols (6a-u). Structural elucidation was done by IR, 1H-NMR and El-MS techniques

Results: 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol (4) was synthesized as the parent molecule and was characterized by IR and the spectrum showed peaks resonating at (cm⁻¹) 2925 (Ar-H), 2250 (S-H), 1593 (C=N) and 1527 (Ar C=C); 1H-NMR spectrum showed signals at δ 11.00 (s, 1H, NH-1'), 7.49 (br.d, J = 7.6 Hz, 1H, H-4'), 7.37 (br.d, J = 8.0 Hz, 1H, H-7'), 7.34 (br.s, 1H, H-2'), 7.09 (t, J = 7.6 Hz, 1H, H-5'), 7.00 (t, J = 7.6 Hz, 1H, H-6') and 4.20 (s, 2H, CH2-10'). EI-MS presented different fragments peaks at m/z 233 (C₁₁H₉N₃OS)⁺ [M+2]⁺, 231 (C₁₁H₉N₃OS)⁺ [M]⁺, 158 (C₁₀H₈NO)⁺, 156 (C₁₀H₈N₂)⁺, 130 (C₉H₈N)⁺. The derivatives (6a-6u) were prepared and characterized accordingly. **Conclusion:** S-alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiols (6a-u) were successfully synthesized.

Keywords: 2-(1H-indole-3-ylmethyl)-1,3,4-oxadiazole-5-thiol, S-alkylated/aralkylated derivatives, Synthesis, Characterization, ¹H-NMR and EI-MS

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

The synthesis and analysis of chemical and biological behaviors of 2, 5-disubstituted-1,3,4-oxadiazole-2-thiol derivatives have gained substantive importance in the past few decades for biological, medical and agricultural reasons [1-5]. Synthesis of 2,5-disubstituted 1,3,4-

oxadiazoles from acyl hydrazides and acids can be done by acid activation with CDI, followed by coupling with the required acyl hydrazide and dehydration in the same pot with CBr_4 and Ph_3P [6]. The appropriate aromatic acids are transformed to corresponding oxadiazoles through their hydrazides [7,8]. Substitution of alkyl/aralkyl halides can be done at 1, 3, 4oxadiazole-2-thiol, to study structure-activity relationship [9].

Indole derivatives display a wide range of biological activities. 2-(1H-indol-3-yl) acetic acid is a plant growth hormone. It is obtained naturally from diets rich in vegetable stems and is synthesized from tryptophan, which is also used for the hormones serotonin and melatonin, the anti-inflammatory drug indomethacin. the psychotropic drug LSD and the anti-tumor agent vinblastine [10,11]. In continuation of our ongoing research efforts [12,13], we report herein the synthesis of alkylated/aralkylated 2-[1H-indol-3ylmethyl]-1,3,4-oxadiazole-5-thiols (6a-u) which might be employed for pharmacological evaluation in search of new drug candidates.

EXPERIMENTAL

Materials and instruments

Alkyl halides were purchased from Sigma Aldrich and Alfa Aesar, while 3-indoleacetic acid and hydrated hydrazine were from DAE Jung. All solvents were obtained through local supplier and used after distillation. Thin layer chromatography (TLC) was carried out on precoated silica gel G-25-UV₂₅₄ plates, run in different ratios of EtOAc and n-hexane and visualized at UV 254 nm. Melting points of synthesized compounds were recorded on Griffin and George melting point apparatus by open capillary tube and were uncorrected; IR spectra, was recorded in KBr pellet method on a Jasco-320-A spectrometer (Germany) in cm⁻¹; ¹H-NMR spectra were recorded in DMSO on a Bruker spectrometer (USA) at 300, 400 & 500 MHz with chemical shifts in ppm; and EIMS spectra were recorded on a JMS-HX-110 spectrometer with a data system.

Synthesis

Ethyl 2-(1H-indol-3-yl)acetate (2): 2-(1H-indol-3-yl)acetic acid (20.0 g; 0.11 mol; 1) in absolute ethanol (60 mL) and catalytic amount of concentrated sulfuric acid (10 mL; 0.18 mol) were put into a round bottomed flask and refluxed for 8 h. The flask contents were then neutralized with 25 mL of 10 % Na₂CO₃ solution. The product was isolated by solvent extraction with chloroform.

2-(1H-indol-3-yl)acetohydrazide (3): Ethyl 2-(1H-indol-3-yl) acetate (19.0 mL; **2**) and 80 % hydrazine hydrate (25 mL) in 30 mL methanol were put into a round bottomed flask. The

reaction mixture was stirred for 3 h at room temperature and the resultant acid hydrazide was obtained by distilling methanol from the reaction mixture.

2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-

thiol (4): 2-(1H-indol-3-yl) acetohydrazide (20.0 g, 0.11 mol; **3**) and absolute ethanol (30 mL) were put into a round bottom flask. Carbon disulfide (14.0 mL, 22 mol) was then added to the solution, followed by addition of potassium hydroxide (6.3 g, 0.11 mol). The mixture was refluxed for 6 h. and then diluted with distilled water (50 mL) and acidified with dilute hydrochloric acid to pH 2-3. The precipitate thus formed was filtered, washed with water and recrystallized in ethanol.


S-alkylated/aralkylated 2-(1H-indol-3-

ylmethyl)-1, 3, 4-oxadiazole-5-thiols (6a-u): 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiol (0.20 g; 0.001 mol; 4) as a nucleophile in N,Ndimethyl formamide was placed in a round bottom flask followed by addition of sodium hydride (0.002 g, 0.1 mmol) to the reaction mixture, which was then stirred for about half an hour at room temperature. The electrophiles, alkyl/aralkyl halides (**5a-5u**), were added in stoichiometric amounts and stirred for 8 h. After completion of reaction, the derivatives (**6a-6u**) were obtained as precipitates by addition of distilled water or by solvent extraction depending on the nature of the product.

RESULTS

The S-substituted derivatives (**6a-6u**) of 2-(1*H*indol-3-yl-methyl)-1,3,4-oxadiazole-5-thiol (**4**) were synthesized by the protocol sketched in **Scheme 1** and the different S-substituted alkyl/aralkyl groups are listed in **Table 1** while the spectral and mass fragmentation patterns are shown in Fig 1-4. The spectral characterizations of the compounds are provided below.

2-(1*H***-indol-3-yl)acetate (2):** Brownish liquid, Yield: 85 %; Molecular formula: $C_{12}H_{13}NO_2$; Molecular weight: 203 gmol⁻¹; IR (KBr) v_{max} : 3315 (N-H), 2930 (Ar-H), 1624 (C=O), 1531 (Ar. C=C); ¹H-NMR (400 MHz, DMSO-*d*₆): δ 10.9 (s, 1H, NH-1'), 7.48 (br.d, *J* = 8.0 Hz, 1H, H-4'), 7.34 (br.d, *J* = 8.0 Hz, 1H, H-7'), 7.23 (br.s, 1H, H-2'), 7.06 (t, *J* = 7.6 Hz, 1H, H-5'), 6.97 (t, *J* = 7.6 Hz, 1H, H-6'),4.16 (q, *J*= 7.2, 2H, -O<u>CH</u>₂CH₃), 3.71 (s, 2H, CH₂-10'),1.17 (t, *J* = 7.2 Hz, 3H, -OCH₂<u>CH</u>₃). EIMS: *m*/*z* 203 (C₁₂H₁₃NO₂)⁺ [M]⁺, 158 (C₁₀H₈NO)⁺, 130 (C₉H₈N)⁺, 73 (C₃H₅O₂)⁺. Rubab et al



Scheme 1: Steps in the synthesis of S-alkylated/aralkylated 2-(1*H*-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiols (6a-6u)

Table 1: S-Alkylated/aralkylated 2-(1H-indol-3-ylmethyl)-1,3,4-oxadiazole-5-thiols (6a-u	Table 1: S-Alkylate	d/aralkylated 2-(1H-inc	dol-3-ylmethyl)-1,3,4-oxad	diazole-5-thiols (6a-u
--	---------------------	-------------------------	----------------------------	------------------------

Cod e	R	Cod e	R	Cod e	R
6a		6h		60	-CH2-CH
6b	-CH ₂ -CH ₂ -CI 1" 2"	6i	H -CH2 2" 3" H _b	6р	-CH ₂ -(1"-3")-CI
6c	-CH ₂ -CH ₂ -CH ₃ 1" 2" 3"	6j	$-H_2C \xrightarrow{O^{\text{m}}}_{C} O \xrightarrow{T^{\text{m}}}_{H_2} O^{\text{m}}_{H_2}$	6q	-CH ₂ -U-3"
6d	-CH ₃ -CH ₃ -CH ₃ -CH ₃ -CH ₃	6k	-CH ₂ -(1"3")	6r	-CH ₂ -(1"3")-Br
6e	4" CH ₃ – CH – CH ₂ – CH ₃ 1" 2" 3"	61	$-H_2C-CH_2-(1)$	6s	-CH ₂ - CH 2- T
6f	$-CH_2 - CH_2 - CH_2 - CH_3 1" 2" 3" 4"$	6m	$-H_2C - H_2C - CH_2 - 1 5$	6t	H ₃ C -CH ₂ -1•3• 5•
6g		6n	CI -CH ₂ -(1" 3") -CH ₂ -(1" 5")	6u	-CH ₂ -(1"-3") 5

Rubab et al




Figure 1: ¹H-NMR spectrum of 3-{[5-(AllyIsulfanyI)-1,3,4-oxadiazol-2-yl]methyl}-1*H*-indole (6i)




Figure 2: ¹H-NMR spectrum of 3-[(5-(Ethoxycarbonylmethylsulfanyl)-1,3,4-oxadiazole-2-yl)methyl]-1H-indole (6j)

2-(1*H***-indol-3-yl)acetohydrazide (3):** Brownish crystals; Yield: 89 %; M.P. 113 °C; Molecular formula: C₁₀H₁₁N₃O; Molecular weight: 189 gmol⁻¹; IR (KBr) v_{max} : 3310 (N-H), 2930 (Ar-H), 1630 (C=O), 1529 (Ar. C=C); ¹H-NMR (400 MHz, DMSO-*d*₆): δ 10.8 (s, 1H, NH-1'),9.08 (s, 1H, <u>NH</u>NH₂), 7.55 (br.d, *J* = 7.6 Hz, 1H, H-4'), 7.31 (br.d, *J* = 8.0 Hz, 1H, H-7'), 7.16 (br.s, 1H, H-2'), 7.04 (t, *J* = 7.2 Hz, 1H, H-5'), 6.95 (t, *J* = 7.6 Hz, 1H, H-6'), 4.16 (s,1H, NH<u>NH₂</u>) 3.43 (s, 2H, CH₂-10'). EIMS: *m/z* 203 (C₁₀H₁₁N₃O)⁻⁺ [M]⁺, 158 (C₁₀H₈NO)⁺, 130 (C₉H₈N)⁺, 59 (C₃H₅O₂)⁺.

2-(1*H***-indol-3-yl-methyl)-1,3,4-oxadiazole-5thiol (4):** Dark brown powder; Yield: 76 %; M.P. 125 °C; Molecular formula: $C_{11}H_9N_3OS$; Molecular weight: 231 gmol⁻¹; IR (KBr) v_{max} : 2925 (Ar-H), 2250 (S-H), 1593 (C=N), 1527 (Ar C=C) ; ¹H-NMR (400 MHz, DMSO- d_6): δ 11.0 (s, 1H, NH-1'), 7.49 (br.d, J = 7.6 Hz, 1H, H-4'), 7.37 (br.d, J = 8.0 Hz, 1H, H-7'), 7.34 (br.s, 1H, H-2'), 7.09 (t, J = 7.6 Hz, 1H, H-5'), 7.00 (t, J = 7.6 Hz, 1H, H-6'), 4.20 (s, 2H, CH₂-10'). EIMS: m/z 233 ($C_{11}H_9N_3OS$)⁻⁺ [M+2]⁺, 231 ($C_{11}H_9N_3OS$)⁻⁺ [M]⁺, 158 ($C_{10}H_8NO$)⁺, 156 ($C_{10}H_8N_2$)⁻⁺, 130 (C_9H_8N)⁺. Rubab et al




Figure 3: ¹H-NMR spectrum of 3-({5-[(3-nitrobenzyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6u)




Fig 4: Mass fragmentation pattern 3-({5-[(3-nitrobenzyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6u)

3-({5-[(2-Bromoethyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1*H*-indole (6a): Light brown amorphous solid; Yield: 81 %; M.P. 146 °C; Molecular formula: $C_{13}H_{12}N_3OSBr$; Molecular weight: 338 gmol⁻¹; IR (KBr): v_{max} 3226 (N-H), 2910 (C-H Ar), 1484 (C=N), 1476 (C=C Ar), 840 (C-N) and 810 (C-S); ¹H-NMR (300 MHz,

DMSO-*d*₆): δ 11.0 (s, 1H, NH-1'), 7.47 (br.d, *J* = 7.8 Hz, 1H, H-4'), 7.35 (br.d, *J* = 7.8 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.09 (t, *J* = 6.9 Hz, 1H, H-5'), 6.98 (t, *J* = 7.2 Hz, 1H, H-6'), 4.13 (s, 2H, CH₂-10'), 3.22-3.25 (m-overlapped, 4H, CH₂-1" & CH₂-2"); EIMS: *m/z* 341 (C₁₃H₁₂N₃OSBr)⁻⁺ [M+4]⁺, 339 (C₁₃H₁₂N₃OSBr)⁻⁺ [M+2]⁺, 337

Trop J Pharm Res, July 2016; 15(7): 1519

 $\begin{array}{ll} (C_{13}H_{12}N_3OSBr)^{\cdot \dagger} & [M]^{\dagger}, \ 233 \ (C_{11}H_9N_3OS)^{\dagger}, \ \ 231 \\ (C_{11}H_9N_3OS)^{\dagger}, \ \ 198 \ \ (C_{11}H_8N_3O)^{\dagger}, \ \ 172 \\ (C_{10}H_8NO)^{\dagger}, \ \ 170 \ \ (C_{10}H_8N_3)^{\dagger}, \ \ 158 \ \ (C_{10}H_8NO)^{\dagger}, \\ 158 \ (C_6H_4Br+2)^{\dagger}, \ 156 \ \ (C_6H_4Br)^{\dagger}, \ 156 \ \ (C_{10}H_8N_2)^{\cdot \dagger}, \\ 130 \ \ (C_9H_8N)^{\dagger}, \ \ 110 \ \ (C_2H_4Br)^{\dagger}, \ 108 \ \ (C_2H_4Br)^{\dagger}. \end{array}$

3-({5-[(2-Chloroethyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1*H*-indole (6b): Light brown amorphous solid; Yield: 85 %; M.P. 208 °C; Molecular formula: C13H12N3OSCI; Molecular weight: 293.5 gmol⁻¹; IR (KBr): v_{max}: 3221 (N-H), 2919 (C-H Ar), 1484 (C=N), 1470 (C=C Ar), 843 (C-N) and 814 (C-S); ¹H-NMR (500 MHz, DMSO d_6): δ 10.99 (s, 1H, NH-1'), 7.51 (br.d, J = 8.0Hz, 1H, H-4'), 7.38 (br.d, J = 8.0 Hz, 1H, H-7'), 7.33 (br.s, 1H, H-2'), 7.10 (t, J = 8.0 Hz, 1H, H-5'), 7.00 (t, J = 8.0 Hz, 1H, H-6'), 4.34 (s, 2H, CH₂-10'), 3.91 (t, 2H, J = 7.0 Hz, CH₂-2"), 3.56 (t, 2H, J = 7.0 Hz, CH₂-1"); EIMS: m/z 297 $(C_{11}H_9N_3OS+2)^{+}$, 293 $(C_{13}H_{12}N_3OSCI)^{+}$ $(C_{14}H_9N_3OS+2)^{+}$, 231 $(C_{14}H_2N_4OS^{+})^{+}$ (C₁₃H₁₂N₃OSCI)⁺⁺ [M+4]⁺, 295 (C₁₃H₁₂N₃OSCI)⁺⁺ [M]⁺, 233 231 (C₁₁H₉N₃OS)⁺, 198 $(C_{11}H_8N_3O)^+$, 172 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{-+}$, 130 $(C_9H_8N)^+$, $65 (C_2H_4CI+2)^+$, $63 (C_2H_4CI)^+$.

3-{[5-(Propylsulfanyl)-1,3,4-oxadiazol-2-

yl]methyl}-1*H*-indole (6c): Brown amorphous solid; Yield: 70 %; M.P. 103°C; Molecular formula: $C_{14}H_{15}N_3OS$; Molecular weight: 273 gmol⁻¹; IR (KBr): v_{max} : 3225 (N-H), 2932 (C-H Ar), 1479 (C=N), 1474 (C=C Ar), 840 (C-N) and 816 (C-S); ¹H-NMR (400 MHz, DMSO-*d*₆): δ 11.0 (s, 1H, NH-1'), 7.47 (br.d, *J* = 7.6 Hz, 1H, H-4'), 7.35 (br.d, *J* = 7.6 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.09 (t, *J* = 6.8 Hz, 1H, H-5'), 6.98 (t, *J* = 7.2 Hz, 1H, H-6'), 4.16 (s, 2H, CH₂-10'), 3.84 (t, *J* = 7.6 Hz, 2H, CH₂-1"), 1.64 (sex, *J* = 7.2 Hz, 2H, CH₂-2"), 1.05 (t, *J* = 7.2 Hz, 3H, CH₃-3"); EIMS: *m*/z 275 (C₁₄H₁₅N₃OS)⁻⁺ [M+2]⁺, 273 (C₁₄H₁₅N₃OS)⁺⁺ [M]⁺, 233 (C₁₁H₉N₃OS+2)⁺, 231 (C₁₁H₉N₃OS)⁺, 198 (C₁₁H₈N₃O)⁺, 172 (C₁₀H₈N₂O)⁺, 170 (C₁₀H₈N₃)⁺, 158 (C₁₀H₈NO)⁺, 156 (C₁₀H₈N₂)⁻⁺, 130 (C₉H₈N)⁺, 43(C₃H₇)⁺.

3-{[5-(iso-Propylsulfanyl)-1,3,4-oxadiazol-2-

yl]methyl}-1*H*-indole (6d): Light brown amorphous solid; Yield: 75 %; M.P. 78 °C; Molecular formula: C14H15N3OS; Molecular weight: 273 gmol⁻¹; IR (KBr): v_{max}: 3225 (N-H), 2928 (C-H Ar), 1478 (C=N), 1470 (C=C Ar), 845 (C-N) and 809 (C-S); ¹H-NMR (500 MHz, DMSO d_6): δ 11.02 (s, 1H, NH-1'), 7.50 (br. d, J = 8.0Hz, 1H, H-4'), 7.37 (br. d, J = 8.0 Hz, 1H, H-7'), 7.33 (br. s, 1H, H-2'), 7.10 (t, J = 7.0 Hz, 1H, H-5'), 7.00 (t, J = 7.5 Hz, 1H, H-6'), 4.78 (s, 2H, CH₂-10'), 3.76-3.71 (m, 1H, CH-1"), 1.36 (d, J = 6.0 Hz, 6H, CH₃-2" & CH₃-3"); EIMS: m/z 275 $\begin{array}{cccc} \left(C_{14}H_{15}N_{3}OS\right)^{,*} & \left[M+2\right]^{,} & 273 & \left(C_{20}H_{19}N_{3}OS\right)^{,*} \\ \left[M\right]^{,} & 233 & \left(C_{11}H_{9}N_{3}OS+2\right)^{,} & 231(& C_{14}H_{15}N_{3}OS)^{,} \end{array}$

3-{[5-(sec-Butylsulfanyl)-1,3,4-oxadiazol-2-

yl]methyl}-1H-indole (6e): Dark brown sticky Yield: 73 %; Molecular formula: solid; C₁₅H₁₇N₃OS; Molecular weight: 287 gmol⁻¹; IR (KBr): v_{max}: 3220 (N-H), 2930 (C-H Ar), 1485 (C=N), 1472 (C=C Ar), 838 (C-N) and 814 (C-S); ¹H-NMR (400 MHz, DMSO-*d*₆): δ 11.0 (s, 1H, NH-1'), 7.47 (br. d, J = 7.6 Hz, 1H, H-4'), 7.35 (br. d, J = 8.0 Hz, 1H, H-7'), 7.31 (br. s, 1H, H-2'),7.09 (t, J = 6.8 Hz, 1H, H-5'), 6.98 (t, J = 7.2 Hz, 1H, H-6'), 4.43 (s, 2H, CH₂-10'), 4.25-4.21 (m, 1H, H-1"), 1.01 (d, J = 6.8 Hz, 3H, CH₃-4"), 0.90-0.85 (m, 2H, H-2"), 0.74 (t, J = 7.2 Hz, 3H, CH₃-3"). EIMS: *m*/*z* 289 (C₁₅H₁₇N₃OS)^{.+} [M+2]⁺, 287 $(C_{15}H_{17}N_3OS)^+$ $[M]^+$, 233 $(C_{11}H_9N_3OS+2)^+$, 231 $(C_{11}H_9N_3OS)^{+}$, 198 $(C_{11}H_8N_3O)^{\dagger}$, 172 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{-+}$, 130 $(C_9H_8N)^+$, 58 $(C_4H_9)^+$, 43 $(C_3H_6)^{.+}$.

3-{[5-(Butylsulfanyl)-1,3,4-oxadiazol-2-

yI]methyI}-1*H***-indole (6f):** Brown amorphous solid; Yield: 87 %; M.P. 83 °C; Molecular formula: $C_{15}H_{17}N_3OS$; Molecular weight: 287 gmol⁻¹; IR (KBr): v_{max} : 3220 (N-H), 2925 (C-H Ar), 1480 (C=N), 1477 (C=C Ar), 839 (C-N) and 805 (C-S); ¹H-NMR (500 MHz, DMSO-*d*₆): δ 11.02 (s, 1H, NH-1'), 7.49 (br. d, *J* = 8.0 Hz, 1H, H-4'), 7.37 (br.d, *J* = 8.5 Hz, 1H, H-7'), 7.32 (br.s, 1H, H-2'), 7.09 (t, *J* = 8.0 Hz, 1H, H-5'), 6.99 (t, *J* = 7.5 Hz, 1H, H-6'), 4.25 (s, 2H, CH₂-10'), 3.15 (t, *J* = 7.5 Hz, 2H, CH₂-1''), 1.61 (quint., *J* = 7.5 Hz, 2H, CH₂-2''), 1.31 (sext, *J* = 7.0 Hz, 2H, CH₂-3''), 0.84 (t, *J* = 7.5 Hz, 3H, CH₃-4''). EIMS: *m/z* 289 ($C_{15}H_{17}N_3OS$)⁻⁺ [M]⁺, 287 ($C_{15}H_{17}N_3OS$)⁻⁺ [M]⁺, 233 ($C_{11}H_9N_3OS+2$)⁺, 231 ($C_{11}H_9N_3OS$)⁺, 172 ($C_{10}H_8N_2O$)⁺, 170 ($C_{10}H_8N_3$)⁺, 158 ($C_{10}H_8NO$)⁺, 156 ($C_{10}H_8N_2$)⁻⁺, 130 (C_9H_8N)⁺, 58 (C_4H_9)⁺, 42 (C_3H_6)⁻⁺.

3-{[5-(Pentylsulfanyl)-1,3,4-oxadiazol-2-

yI]methyI}-1*H***-indole (6g):** Brown amorphous solid; Yield: 78 %; M.P. 62 °C; Molecular formula: $C_{16}H_{19}N_3OS$; Molecular weight: 301 gmol⁻¹; IR (KBr): v_{max} : 3224 (N-H), 2927 (C-H Ar), 1484 (C=N), 1470 (C=C Ar), 847 (C-N) and 812 (C-S); ¹H-NMR (500 MHz, DMSO-*d*₆): δ 11.03 (s, 1H, NH-1'), 7.46 (br. d, *J* = 8.0 Hz, 1H, H-4'), 7.33 (br. d, *J* = 8.0 Hz, 1H, H-7'), 7.29 (br. s, 1H, H-2'), 7.06 (t, *J* = 7.0 Hz, 1H, H-5'), 6.96 (t, *J* = 7.5 Hz, 2H, CH₂-1"), 1.61 (quint., 2H, CH₂-2"), 1.38-1.17 (m, 4H, CH₂-3", CH₂-4"), 0.79 (t, *J* = 7.0 Hz, 3H, CH₃-5"); EIMS: *m/z m/z* 303 ($C_{16}H_{19}N_3OS$)⁻⁺ [M+2]⁺, 301 ($C_{16}H_{19}N_3OS$)⁺⁺ [M]⁺, 233 ($C_{11}H_9N_3OS+2$)⁺, 231 ($C_{11}H_9N_3OS$)⁺, 198

 $(C_{11}H_8N_3O)^+$, 172 $(C_{10}H_8NO)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{-+}$, 130 $(C_9H_8N)^+$, 71 $(C_5H_{11})^+$, 55 $(C_4H_7)^{-+}$.

3-{[5-(Heptylsulfanyl)-1,3,4-oxadiazol-2-

yl]methyl}-1*H*-indole (6h): Dark brown amorphous solid; Yield: 88 %; M.P. 133 °C; Molecular formula: C₁₈H₂₃N₃OS; Molecular weight: 329 gmol⁻¹; IR (KBr): *v*_{max}: 3225 (N-H), 2931 (C-H Ar), 1480 (C=N), 1475 (C=C Ar), 845 (C-N) and 810 (C-S); ¹H-NMR (400 MHz, DMSO d_6): δ 11.0 (s, 1H, NH-1'), 7.47 (br.d, J = 7.6 Hz, 1H, H-4'), 7.35 (br.d, J = 7.6 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.09 (t, J = 6.8 Hz, 1H, H-5'), 6.98 (t, J = 7.2 Hz, 1H, H-6'), 4.17 (s, 2H, CH₂-10'),3.67-3.64 (m, 1H, H-1"), 2.02-1.97 (m, 4H, H-2" & H-3"), 1.25-1.18 (m, 6H, H-4" to H-6"), 0.82 (t, J = 7.2 Hz, 3H, CH₃-7"); EIMS: *m/z* 331 $(C_{18}H_{23}N_3OS)^{+}$ [M+2]⁺, 329 $(C_{18}H_{23}N_3OS)^{+}$ [M]⁺, $\begin{array}{c} 233 \quad (C_{11}H_9N_3OS+2)^{+}, \quad 231 \quad (C_{11}H_9N_3OS)^{+}, \quad 198 \end{array}$ $\begin{array}{c} (C_{11}H_8N_3O)^+, \ 172 \ (C_{10}H_8N_2O)^+, \ 170 \ (C_{10}H_8N_3)^+, \\ 158 \ (C_{10}H_8NO)^+, \ 156 \ (C_{10}H_8N_2)^{\cdot+}, \ 130 \ (C_9H_8N)^+, \\ 99 \ (C_7H_{14})^+, \ 84 \ (C_6H_{12})^{\cdot+}, \ 56 \ (C_4H_8)^{\cdot+}. \end{array}$

3-{[5-(AllyIsulfanyI)-1,3,4-oxadiazol-2-

yl]methyl}-1H-indole (6i): Dark brown shiny solid; Yield: 76 %; M.P. 105 °C; Molecular formula: C14H14N3OS; Molecular weight: 272 gmol⁻¹; IR (KBr): v_{max}: 3226 (N-H), 2933 (C-H Ar), 1481 (C=N), 1470 (C=C Ar), 843 (C-N) and 812 (C-S); ¹H-NMR (500 MHz, DMSO- d_6): δ 11.01 (s, 1H, NH-1'), 7.48 (br.d, J = 8.0 Hz, 1H, H-4'), 7.36 (br.d, J = 8.5 Hz, 1H, H-7'), 7.31 (br. s, 1H, H-2'), 7.08 (t, J = 7.5 Hz, 1H, H-5'), 6.98 (t, J = 8.0 Hz, 1H, H-6'), 5.90-5.80 (m, 1H, H-2"), 5.14 (dd, J = 17.0, 1.5 Hz, 1H, H_{b} -3"), 5.08 (dd, J = 10.0, 0.5Hz, 1H, H_a-3"), 4.31 (s,2H, CH₂-10'), 3.80 (d, J = 6.9 Hz, 2H, CH₂-1"). EIMS: *m*/z 274 $(C_{14}H_{14}N_3OS)^{+}$ [M+2]⁺, 272 $(C_{14}H_{14}N_3OS)^{+}$ [M]⁺, $\begin{array}{c} (C_{14} H_{14} H_{3} C_{3} C_{3})^{\dagger} & [HII 2] \\ (C_{11} H_{9} H_{3} OS + 2)^{\dagger}, \\ (C_{11} H_{9} H_{3} OS + 2)^{\dagger}, \\ (C_{11} H_{8} H_{3} O)^{\dagger}, \\ (C_{10} H_{8} H_{2} O)^{\dagger}, \\ (C_{10} H_{8} H_{3} O)^{\dagger},$ 41 $(C_3H_5)^{T}$.

3-[(5-(Ethoxycarbonylmethylsulfanyl)-1,3,4-

oxadiazole-2-yl)methyl]-1H-indole (6j): Dark brown shiny solid; Yield: 82 %; M.P. 97 °C; Molecular formula: C₁₅H₁₅N₃O₃S; Molecular weight: 317 gmol⁻¹; IR (KBr): v_{max} : 3225 (N-H), 2934 (C-H Ar), 1484 (C=N), 1470 (C=C Ar), 840 (C-N) and 814 (C-S); ¹H-NMR (500 MHz, DMSO d_6): δ 11.04 (s, 1H, NH-1'), 7.48 (br.d, J = 8.0Hz, 1H, H-4'), 7.36 (br.d, J = 8.0 Hz, 1H, H-7'), 7.30 (br.s, 1H, H-2'), 7.08 (t, J = 7.0 Hz, 1H, H-5'), 6.98 (t, J = 8.0 Hz, 1H, H-6'), 4.31 (s, 2H, CH₂-10'), 4.12 (s, 2H, CH₂-1'"), 4.04 (q, J = 7.2 Hz, 2H, CH₂-1"), 1.11 (t, J = 7.0 Hz, 3H, CH₃-2"); EIMS: *m*/*z* 319 (C₁₅H₁₅N₃O₃S)⁺ [M+2]⁺,317 $(C_{15}H_{15}N_{3}O_{3}S)^{+}$ [M]⁺, 233 $(C_{11}H_{9}N_{3}OS+2)^{+}$, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^{+}$, 172

3-{[5-(Benzylsulfanyl)-1,3,4-oxadiazol-2-

(6k): Light yl]methyl}-1*H*-indole brown amorphous solid; Yield: 79 %; M.P. 110 °C; Molecular formula: C₁₈H₁₅N₃OS; Molecular weight: 321 gmol⁻¹; IR (KBr): *v*_{max}: 3224 (N-H), 2928 (C-H Ar), 1486 (C=N), 1477 (C=C Ar), 838 (C-N) and 810 (C-S); ¹H-NMR (400 MHz, DMSO d_6): δ 11.02 (s, 1H, NH-1'), 7.49 (br.d, J = 8.0 Hz, 1H, H-4'), 7.38 (br.d, J = 8.5 Hz, 1H, H-7'), 7.32 (br.s, 1H, H-2'), 7.28-7.25 (m, 2H, H-2"& H-6"), 7.24- 7.19 (m, 3H, H-3" to H-5"), 7.11 (t, J = 8.0 Hz, 1H, H-5'), 7.00 (t, J = 8.0 Hz, 1H, H-6'), 4.35 (s, 2H, CH₂-10'), 4.25 (s, 2H, CH₂-7"); EIMS: 323 [M+2]⁺, m/z (C₁₈H₁₅N₃OS)⁻¹ 321 $(C_{18}H_{15}N_3OS)^{+}$ [M]⁺, 233 $(C_{11}H_9N_3OS+2)^{+}$, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^{+}$, 172 $(C_{10}H_8N_2O)^{\dagger}$, 170 $(C_{10}H_8N_3)^{\dagger}$, 158 $(C_{10}H_8NO)^{\dagger}$, 156 $(C_{10}H_8N_2)^+$, 130 $(C_9H_8N)^+$,91 $(C_7H_7)^+$, 65 $(C_5H_5)^{+}$.

3-({5-[(3-Phenylethyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6l): Dark brown solid; Yield: 80 %; M.P. 75 °C; Molecular formula: C₁₉H₁₇N₃OS; Molecular weight: 335 gmol⁻¹; IR (KBr): v_{max}: 3215 (N-H), 2930 (C-H Ar), 1485 (C=N), 1479 (C=C Ar), 846(C-N) and 810 (C-S); ¹H-NMR (400 MHz, DMSO-*d*₆): δ 11.0 (s, 1H, NH-1'), 7.49 (br.d, J = 7.6 Hz, 1H, H-4'), 7.36 (br.d, J = 8.0 Hz, 1H, H-7'), 7.33 (br.s, 1H, H-2'),7.26-7.22 (m, 3H, H-3", H-4" & H-5"), 7.18-7.12 (m,2H, H-2" & H-6"), 7.09 (t, J = 7.6 Hz, 1H, H-5'), 6.98 (t, J = 7.6 Hz, 1H, H-6'), 4.32 (s, 2H, CH₂-10'), 3.39 (t, J = 7.2 Hz, 2H, CH₂-8"), 2.95 (t, J = 7.6 Hz, 2H, CH₂-7"); EIMS: m/z 337 (C₁₉H₁₇N₃OS)⁺ [M+2]⁺, 335 (C₁₉H₁₇N₃OS)⁺ $[M]^+$, 233 $(C_{11}H_9N_3OS+2)^+$, 231 $(C_{11}H_9N_3OS)^+$, $(C_5H_5)^+$.

3-({5-[(3-Phenylpropyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1*H***-indole (6m): Dark brown shiny powder; Yield: 77 %; M.P. 64 °C; Molecular formula: C_{20}H_{19}N_3OS; Molecular weight: 349 gmol⁻¹; IR (KBr): v_{max}: 3225 (N-H), 2927 (C-H Ar), 1484 (C=N), 1476 (C=C Ar), 847 (C-N) and 812 (C-S); ¹H-NMR (300 MHz, DMSOd_6): \delta 11.0 (s, 1H, NH-1'), 7.47 (br.d, J = 7.8 Hz, 1H, H-4'), 7.35 (br.d, J = 7.8 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.27-7.23 (m, 3H, H-3", H-4" & H-5"), 7.18-7.12 (m,2H, H-2" & H-6"),7.08 (t, J = 7.2 Hz, 1H, H-5'), 6.97 (t, J = 6.9 Hz, 1H, H-6'), 4.31 (s, 2H, CH₂-10'), 3.15 (t, J = 7.2 Hz, 2H, CH₂-9"), 2.63 (t, J = 8.1 Hz, 2H, CH₂-7"), 1.94 (quint., J = 7.5 Hz, 2H, CH₂-8"); EIMS:** *m/z* **351** $\begin{array}{l} (C_{20}H_{19}N_3OS)^{,*} \ \left[M+2\right]^{,} \ 349 \ (C_{20}H_{19}N_3OS)^{,*} \ \left[M\right]^{,} \\ 233 \ (C_{11}H_9N_3OS+2)^{,} \ 231 \ (C_{11}H_9N_3OS)^{,} \ 198 \\ (C_{11}H_8N_3O)^{,} \ 172 \ (C_{10}H_8N_2O)^{,} \ 170 \ (C_{10}H_8N_3)^{,} \\ 158 \ (C_{10}H_8NO)^{,} \ 156 \ (C_{10}H_8N_2)^{,*} \ 130 \\ (C_{9}H_8N)^{,} \ 119 \ (C_{9}H_{11})^{,} \ 91 \ (C_{7}H_7)^{,} \ 65 \ (C_{5}H_5)^{,} \end{array}$

3-({5-[(2-Chlorobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6n): Dark brown amorphous solid; Yield: 83 %; M.P. 126 °C; Molecular formula: C₁₈H₁₄N₃OSCI; Molecular weight: 355.5 gmol⁻¹; IR (KBr): v_{max} : 3230 (N-H), 2929 (C-H Ar), 1480 (C=N), 1472 (C=C Ar), 8441(C-N) and 812 (C-S); ¹H-NMR (400 MHz, DMSO- d_6): δ 11.0 (s, 1H, NH-1'), 7.47 (br.d, J =8.0 Hz, 1H, H-4'), 7.35 (br.d, J = 7.6 Hz, 1H, H-7'), 7.34 (br.s, 1H, H-2'),7.32 (dd, J = 1.2, 8.0 Hz, 1H, H-3"), 7.29 (br.d, J = 7.6 Hz, 1H, H-6"), 7.16-7.10 (m, 2H, H-4" & H-5"), 7.08 (t, J = 7.2 Hz, 1H, H-5'), 6.97 (t, J = 6.8 Hz, 1H, H-6'), 4.55 (s, 2H, CH2-7"), 4.31 (s, 2H, CH2-10'); EIMS: m/z (C₁₈H₁₄N₃OSCI)⁻ [M+4]⁺, 359 357 $(C_{18}H_{14}N_3OSCI)^{+}$ $[M+2]^{+}$, 355 $(C_{18}H_{14}N_3OSCI)^{+}$ $[M]^{+}$, 233 $(C_{11}H_9N_3OS+2)^{+}$, 231 $(C_{11}H_9N_3OS)^{+}$, 198 $(C_{11}H_8N_3O)^+$, 172 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^+$, 157 $(C_{10}H_8N_2)^+$, 158 $(C_{10}H_8N_2)^+$, 158 130 $(C_9H_8N)^+$, 127 $(C_7H_6CI+2)^+$, 125 $(C_7H_6CI)^+$ 101 $(C_5H_4CI+2)^+$, 99 $(C_5H_4CI)^+$, 90 $(C_7H_6)^+$, 64 $(C_5H_4)^+$.

3-({5-[(3-Chlorobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6o): Dark brown amorphous solid; Yield: 89 %; M.P. 85 °C; Molecular formula: C₁₈H₁₄N₃OSCI; Molecular weight: 355.5 gmol⁻¹; IR (KBr): v_{max}: 3219 (N-H), 2926 (C-H Ar), 1477 (C=N), 1478 (C=C Ar), 840(C-N) and 812 (C-S); ¹H-NMR (300 MHz, DMSO-d₆): δ 11.01 (s, 1H, NH-1'), 7.39 (br.s, 1H, H-2"), 7.36 (br.d, J = 8.6 Hz, 1H, H-4"), 7.35 (br.d, J = 7.5 Hz, 1H, H-6"), 7.33 (br.t, J = 8.1 Hz, 1H, H-5"), 7.31 (br.d, J = 7.8 Hz, 1H, H-4'), 7.30 (br.d, J = 8.1Hz, 1H, H-7'), 7.29 (br.s, 1H, H-2'), 7.11 (t, J = 7.2 Hz, 1H, H-5'), 6.97 (t, J = 7.2 Hz, 1H, H-6'), 4.54 (s, 2H, CH₂-7"), 4.30 (s, 2H, CH₂-[M+4]⁺. 10'); EIMS: *m/z* 359 (C₁₈H₁₄N₃OSCI) 357 (C₁₈H₁₄N₃OSCI)⁻ 355 [M+2]⁺ (C₁₈H₁₄N₃OSCI)⁺ [M]⁺, 233 (C₁₁H₉N₃OS+2)⁺, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^{+}$, 172 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{+}$, 130 $(C_9H_8N)^{+}$, 127 $(C_7H_6CI+2)^{+}$, 125 $(C_7H_6CI)^{+}$, 101 $(C_5H_4CI+2)^{+}$, 99 $(C_5H_4CI)^{+}$, 90 $(C_7H_6)^+$, 64 $(C_5H_4)^+$.

3-({5-[(4-Chlorobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1*H*-indole (6p): Brown colored amorphous solid; Yield: 79 %; M.P. 121 °C; Molecular formula: $C_{18}H_{14}N_3OSCl$; Molecular weight: 355.5 gmol⁻¹; IR (KBr): v_{max} : 3215 (N-H), 2928 (C-H Ar), 1480 (C=N), 1470 (C=C Ar), 840(C-N) and 812 (C-S); ¹H-NMR (300 MHz, DMSO-*d*₆): δ11.01 (s, 1H, NH-1'), 7.49 (br.d, *J* =

7.8 Hz, 1H, H-4'), 7.42 (br.d, J = 7.2 Hz, 1H, H-7'), 7.37 (br.d, J = 8.4 Hz, 2H, H-2"& H-6"), 7.35 (br.s, 1H, H-2'), 7.30 (br.d, J = 8.4 Hz, 2H, H-3" & H-5"), 7.09 (t, J = 6.9 Hz, 1H, H-5'), 6.98 (t, J = 7.2 Hz, 1H, H-6'), 4.55 (s, 2H, CH2-7"), 4.31 (s, 2H, CH₂-10'); EIMS: *m*/z 359 (C₁₈H₁₄N₃OSCI) [M+4]⁺, 357 (C₁₈H₁₄N₃OSCI)^{.+} [M+2]⁺, 355 $(C_{18}H_{14}N_3OSCI)^{+}$ $[M]^{+}$, 233 $(C_{11}H_9N_3OS+2)^{+}$, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^+$, 172 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^-$, 130 $(C_9H_8N)^+$, 127 $(C_7H_6CI+2)^+$, 125 $(C_7H_6CI)^+$, 101 $(C_5H_4CI+2)^+$, 99 $(C_5H_4CI)^+$, 90 $(C_7H_6)^+$, 64 $(C_5H_4)^+$.

3-({5-[(2-Bromobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6g): Light brown amorphous solid; Yield: 85 %; M.P. 133 °C; Molecular formula: C₁₈H₁₄N₃OSBr; Molecular weight: 399 gmol⁻¹; IR (KBr): v_{max}: 3217 (N-H), 2935 (C-H Ar), 1479 (C=N), 1481 (C=C Ar), 846 (C-N) and 816 (C-S); ¹H-NMR (400 MHz, DMSO d_6): δ 11.02 (s, 1H, NH-1'), 7.47 (br.d, J = 7.6 Hz, 1H, H-4'), 7.35 (br.d, J = 7.6 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.29 (dd, J = 1.2, 8.0 Hz, 1H, H-3"), 7.28 (br.d, J = 7.6 Hz, 1H, H-6"), 7.11-7.09 (m, 2H, H-4" & H-5"), 7.07 (t, J = 7.2 Hz, 1H, H-5'), 6.96 (t, J = 7.6 Hz, 1H, H-6'), 4.55 (s, 2H, CH2-7"), 4.29 (s, 2H, CH2-10'); EIMS: m/z 403 $(C_{18}H_{14}N_3OSBr)^{+}$ [M+4]⁺, 401 $(C_{18}H_{14}N_3OSBr)^{+}$ $[M+2]^{+}$, 399 ($C_{18}H_{14}N_{3}OSBr$)⁺⁺ ($C_{11}H_{9}N_{3}OS+2$)⁺, 231 ($C_{11}H_{9}N_{3}OS+2$)⁺ [M][⁺], 233 (C₁₁H₉N₃OS)⁺, 198 $(C_{11}H_8N_3O)^{\dagger}$, 172 $(C_{10}H_8N_2O)^{\dagger}$, 171 $(C_7H_6Br+2)^+$, 169 $(C_7H_6Br)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{-+}$, 130 $(C_9H_8N)^+$, 90 $(C_7H_6)^+$, 145 $(C_5H_4Br+2)^+$, 143 $(C_5H_4Br)^+$, 64 $(C_5H_4)^+$.

3-({5-[(4-Bromobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6r): Light brown amorphous solid; Yield: 86 %; M.P. 130 °C; Molecular formula: C₁₈H₁₄N₃OSBr; Molecular weight: 400 gmol⁻¹; IR (KBr): v_{max} : 3215 (N-H), 2927 (C-H Ar), 1484 (C=N), 1478 (C=C Ar), 848(C-N) and 812 (C-S); ¹H-NMR (300 MHz, DMSO- d_6): δ 11.0 (s, 1H, N-H-1'), 7.45 (br.d, J =7.8, 1H, H-4'), 7.38-7.36 (m, 3H, H-2", H-6" & H-7'), 7.33 (br.s, 1H, H-2'), 7.17 (br.d, J = 8.4 Hz, 2H, H-3" & H-5"), 7.09 (t, J = 6.9 Hz, 1H, H-5'), 6.98 (t, J = 7.2 Hz, 1H, H-6'), 4.35 (s, 2H, CH₂-7"), 4.31 (s, 2H, CH₂-10'); EIMS: m/z 403 (C₁₈H₁₄N₃OSBr)⁺ [M+4]⁺, 401 (C₁₈H₁₄N₃OSBr)⁺ $(C_{18}H_{14}N_{3}OSBr)^{+}$ [M+2]⁺, 399 [M]⁺, 233 $(C_{11}H_9N_3OS+2)^+$, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^{+}$, 172 $(C_{10}H_8N_2O)^{+}$, 171 $(C_7H_6Br+2)^+$, 169 $(C_7H_6Br)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{-+}$, 130 $(C_9H_8N)^+$, 90 $(C_7H_6)^+$, 145 $(C_5H_4Br+2)^+$, 143 $(C_5H_4Br)^+$, 64 $(C_5H_4)^+$.

3-({5-[(4-Fluorobenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6s): Brown amorphous solid; Yield: 90 %; M.P. 84 °C; Molecular formula: C₁₈H₁₄N₃OSF; Molecular weight: 339 gmol⁻¹; IR (KBr): v_{max} : 3245 (N-H), 2932 (C-H Ar), 1485 (C=N), 1480 (C=C Ar), 850 (C-N) and 825 (C-S); ¹H-NMR (400 MHz, DMSO*d*₆): δ 11.0 (s, 1H, N-H-1'), 7.51 (br.d, *J* = 7.4 Hz, 1H, H-4'), 7.38 (br.s, 1H, H-7'), 7.37 (dist. dd, $J_{(a,b\&a, F)} = 8.8, 5.6$ Hz, 2H_b, H-2" & H-6"),7.35 (br.d, J = 8.0 Hz, 1H, H-2'), 7.09 (t, J = 6.9 Hz, 1H, H-5'), 7.00 (t, $J_{(b,a\&b)}^{19} = 8.8$ Hz, 2H_a, H-3" & H-5"), 6.98 (t, J = 7.2 Hz, 1H, H-6'), 4.55 (s, 2H, CH2-7"), 4.31 (s, 2H, CH2-10'); EIMS: m/z 341 $(C_{18}H_{14}N_3OSF)^+$ [M+2]⁺, 339 $(C_{18}H_{14}N_3OSF)^ [M]^{+}$, 233 $(C_{11}H_9N_3OS+2)^{+}$, 231 $(C_{11}H_9N_3OS)^{+}$, $(C_5H_4F)^+$. 64 $(C_5H_4)^+$.

3-({5-[(2-Methylbenzyl)sulfanyl]-1,3,4-

oxadiazol-2-yl}methyl)-1H-indole (6t): Light brown amorphous solid; Yield: 73 %; M.P. 126 °C; Molecular formula: C₁₉H₁₇N₃OS; Molecular weight: 335 gmol⁻¹; IR (KBr): v_{max} : 3245 (N-H), 2930 (C-H Ar), 1480 (C=N), 1470 (C=C Ar), 840 (C-N) and 810 (C-S); 1H-NMR (400 MHz, DMSO- d_6): δ 11.0 (s, 1H, NH-1'), 7.48 (d, J = 8.0Hz, 1H, H-4'), 7.36 (d, J = 8.0 Hz, 1H, H-7'), 7.31 (br.s, 1H, H-2'), 7.14-7.12 (m, 3H, H-3", H-4" & H-5"), 7.09 (t, J = 8.0 Hz, 1H, H-5'), 7.00 (t, J = 7.8 Hz, 1H, H-6'),6.97 (d, J=4.8Hz, 1H, H-6"), 4.41 (s, 2H, CH₂-10'), 4.32 (s, 2H, CH₂-7"), 2.29 (s, 3H, CH₃-2"); EIMS: *m*/*z* 337 (C₁₉H₁₇N₃OS)⁻¹ $\begin{array}{ll} \left[M+2\right]^{+}, & 335 & \left(C_{19}H_{17}N_{3}OS\right)^{+} \\ \left(C_{11}H_{9}N_{3}OS+2\right)^{+}, & 231 & \left(C_{11}H_{12}N_{3}OS\right)^{+} \end{array}$ ${}_{9}H_{17}N_{3}OS)^{+}$ [M]⁺, 231 (C₁₁H₉N₃OS)⁺, 233 198 $(C_{11}H_8N_3O)^{\dagger}$, 172 $(C_{10}H_8N_2O)^{\dagger}$, 170 $(C_{10}H_8N_3)^{\dagger}$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^-$ 130 $(C_9H_8N)^+,105 (C_8H_9)^+, 90 (C_7H)^+, 79 (C_6H_7)^+, 64$ $(C_5H_4)^{-1}$.

3-({5-[(3-Nitrobenzyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1H-indole (6u): Dark brown amorphous solid; Yield: 78 %; M.P. 101 °C; Molecular formula: C₁₈H₁₄N₃OS; Molecular weight: 366 gmol⁻¹; IR (KBr): v_{max} : 3240 (N-H), 2931 (C-H Ar), 1480 (C=N), 1475 (C=C Ar), 845 (C-N) and 820 (C-S); ¹H-NMR (300 MHz, DMSOd₆): δ11.0 (s, 1H, N-H-1'), 8.30 (br.s, 1H, H-2"), 8.08 (d, J = 8.1 Hz, 1H, H-4"), 7.72 (br.d, J = 7.5 Hz, 1H, H-6"), 7.49 (br.d, J = 7.8 Hz, 1H, H-4'), 7.44 (br.t, J = 7.8 Hz, 1H, H-5"), 7.35 (br.d, J = 8.1 Hz, 1H, H-7'), 7.30 (br.s, 1H, H-2'), 7.07 (t, J = 6.9 Hz, 1H, H-5'), 6.96 (t, J = 7.2 Hz, 1H, H-6'), 4.55 (s, 2H, CH₂-7"), 4.29 (s, 2H, CH₂-10'); EIMS: m/z 368 $(C_{18}H_{14}N_4O_3S)^+$ $[M+2]^+$, 366 $(C_{18}H_{14}N_4O_3S)^+$ $[M]^+$, 233 $(C_{11}H_9N_3OS+2)^+$, 231 $(C_{11}H_9N_3OS)^{\dagger}$, 198 $(C_{11}H_8N_3O)^{\dagger}$, 172

 $(C_{10}H_8N_2O)^+$, 170 $(C_{10}H_8N_3)^+$, 158 $(C_{10}H_8NO)^+$, 156 $(C_{10}H_8N_2)^{++}$, 136 $(C_7H_6NO_2)^+$,130 $(C_9H_8N)^+$, 110 $(C_6H_4NO_2)^+$, 64 $(C_5H_4)^+$.

DISCUSSION

In Figures 1 and 2, the ¹H-NMR spectra of the compounds 3-{[5-(AllyIsulfanyI)-1,3,4-oxadiazol-2-yl]methyl}-1H-indole (**6i**) and 3-[(5-(Ethoxycarbonylmethylsulfanyl)-1,3,4-oxadiazole-2-yl)methyl]-1H-indole (6j) are provided. The compound 6u was obtained as a dark brown amorphous solid; yield: 78 % and m. p. 101 °C and the molecular formula C₁₈H₁₄N₃OS was ascertained by counting the number of protons in the ¹H-NMR spectrum and EIMS molecular ion at m/z 366. Infrared spectrum peak demonstrated N-H stretching at 3240 cm⁻¹ and aromatic C-H stretching at 2931 cm⁻¹. C=N stretching was observed at 1480 cm⁻¹ and aromatic C=C stretching at1475 cm⁻¹. C-N gave stretching at 845 cm⁻¹ and C-S at stretching at 820 cm⁻¹. In the aromatic region of 1H-NMR spectrum, a broad singlet at δ 8.30 (s,1H, H-2"), two doublets and one triplet at δ 8.08 (d, J = 8.1 Hz, 1H, H-4"), 7.72 (d, J = 7.5 Hz, 1H, H-6") and 7.44 (t, J = 7.8 Hz, 1H, H-5") acquiring deshielded position due to the vicinity of an electron withdrawing nitro group which confirmed the substitution of 3-nitrobenzyl group on the parent indole-bearing oxadiazole molecule (4). Another set of two doublets appeared at δ 7.49 (J = 7.8 Hz, 1H, H-4') and 7.35 (J = 8.1 Hz, 1H, H-7') having an integration of one proton each for H-4' & H-7' of the indole moiety. A broad singlet of one proton appeared at 5 7.30 (1H, H-2') of indole moiety. Two triplets resonated at δ 7.07 (J = 6.9 Hz, 1H, H-5') and δ 6.96 (J = 7.2 Hz, 1H, H-6') belonging to phenyl ring of indole moiety. In the aliphatic region, a sharp singlet appeared at δ 4.55, a contributor of two methylene protons at C-7", which confirms the attachment of 3-Nitrobenzyl group at the thiol position of 1,3,4oxadizole ring. Another singlet appeared slightly up-field with integration of two protons of C-10' at δ 4.29 (2H, CH₂-10'). EIMS data further supported this structure by revealing base peak at m/z 130 for (C9H8N)⁺ and other major fragments at m/z 231 $(C_{11}H_9N_3OS)^+$, 156 $(C_{10}H_8N_2)^+$, 172 $(C_{10}H_8NO)^+$, 170 $(C_{10}H_8N_3)^+$, 156 158 $(C_{10}H_8NO)^+$ for indole moiety. Fragments of 3-Nitrobenzyl substituent were observed at m/z136 $(C_7H_6NO_2)^+$, 110 $(C_6H_4NO_2)^+$, 64 $(C_5H_4)^+$. On the basis of these features, the structure of compound 6u was given as 3-({5-[(3nitrobenzyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1H-indole. Similarly, the structures of other Salkylated/aralkylated 2-(1H-indole-3-ylmethyl)-1,3,4-oxadiazole-5-thiols were also characterized by spectroscopic techniques.

CONCLUSION

All the synthesized compounds (**6a-6u**) were obtained in good yields and their structures were elucidated by IR, ¹H-NMR, and EI-MS spectral analysis. It is hoped that further studies on possible biological activities of these compounds might produce useful results for the pharmaceutical industries.

DECLARATIONS

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

REFERENCES

- 1. Vijay VD, Nitin VB. Synthesis of 2-Substituted-1,3,4-Oxadiazole Derivatives. Inter J Chem Env Phar. Res 2011; 2(1): 1-4.
- Ravindra KC, Vagdevi HM, Vaidya VP, Padmashali B. Synthesis, antimicrobial and anti-inflammatory activities of 1,3,4-oxadiazoles linked to naphtho[2,1-b]furan. Ind J Chem 2006; 45(B): 2506–2511.
- 3. Farghaly AR, Hussein EK. Synthesis of some new azoles with antiviral potential. ARKIVOC 2006; (xi): 76-90.
- Palaska E, Şahin G, Kelicen P, Durlu NT, Altinok G. Synthesis and anti-inflammatory activity of 1acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4thiadiazoles and 1,2,4-triazole-3-thiones. IIFarmaco 2002; 57: 101-107.

- De Souza AO, Pedrosa MT, Alderete JB, Cruz AF, Prado MA, Alves RB, Silva CL. Cytotoxicity, antitumoral and antimycobacterial activity of tetrazole and oxadiazole derivatives. Pharmazie 2005; 60: 396-397.
- Rajapakse HA, Zhu H, Young MB, Mott BT. A mild and e□cient one pot synthesis of 1,3,4-oxadiazoles from carboxylic acids and acyl hydrazides. Tetrahed Lett 2006; 47: 4827-4830.
- Salimon J, Salih N, Hussien H. Synthesis and Antimicrobial Activity of 1-(5-Mercapto-1,3,4-Oxadiazol-2-yl) -2-(Pyridine-2-ylamino) ethanone. Sains Malaysiana 2011; 40(5): 445-450.
- Jha KK, Abdul Samad, Kumar Y, Shaharyar M, Jain J, Kumar V, Singh P, Khosa RL. Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives. Euro J of Medi Chem 2010; 45: 4963-4967.
- Abbasi MA, Akhtar A, Aziz-ur-Rehman, Nafeesa K, Siddiqui SZ, Khan KM, Ashraf M, Ejaz SA. Synthesis, structural characterization and enzyme inhibition studies on 5-(2-nitrostyryl)-1,3,4-oxadizole-2-thiol derivatives. J Chil Chem Soc 2013; 58: 2186-2190.
- Gordon SA, Barr S, Fry RJM. Origin of urinary auxin in the germfree and conventional mouse Am J Physiol 1972; 222: 399–403
- 11. Murphy JA, Scott KA, Sinclair RS, Lewis N. A new synthesis of indoles. Tetrahed Lett 1963; 38: 7295–7298.
- Abbasi MA, Shahzad B, Aziz-ur-Rehman, Nafeesa K, Rasool S, Ashraf M, Ejaz SA, Ismail H, Mirza B. Synthesis, Spectral Characterization and Bioactivity Studies of Some S-Substituted Derivatives of 5-(4-Chlorophenyl)-1,3,4-Oxadiazole-2-Thiol. World J Pharm Sci 2014; 2(1): 32-40.
- 13. Siddiqui SZ, Abbasi MA, Aziz-ur-Rehman, Irshad M, Shahzad B, Ashraf M, Ahmad I, Lodhi MA, Mirza B, Ismail H, and Akhtar MN. Synthesis, pharmacological evaluation, molecular docking and cytotoxicity studies on some N-substituted 5-[(4-chlorophenoxy) methyl]-1,3,4-oxadiazole-2yl-2-sulfanyl acetamides. Indo Am J Pharm Res 2014; 4(8): 3603-3617